In a late September press release announcing that Christian’s experimental Alzheimer’s drug had significantly slowed the progression of the memory-robbing disease, the company’s chief executive, Haruo Naito, was anything but circumspect. The results of the late-stage study, he said, “proven the amyloid hypothesis.”